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Abstract
Purpose To determine bioelectrical function and
structural changes of the retina in patients with early
stages of Parkinson’s disease (PD).
Materials and methods Thirty-eight eyes of 20
patients with early idiopathic PD and 38 eyes of 20
healthy age- and sex-matched controls were ophthal-
mologically examined, including assessment of dis-
tance best-corrected visual acuity (DBCVA), slit lamp
examination of the anterior and posterior segment of
the eye, evaluation of the eye structures: paramacular
retinal thickness (RT) and retinal nerve fiber layer
(RNFL) thickness with the aid of OCT, and the
bioelectrical function by full-field electroretinogram
(ERG). Additionally, PD patients were interviewed as
to the presence of dopamine-dependent visual func-
tions abnormalities.
Results In patients with early PD, statistically
significant changes in comparison with the control
group were observed in ERG. They contained a
reduction in mean amplitudes of the scotopic a-wave
(rod–cone response), the scotopic oscillatory poten-
tials (OPs)—OP2 and OP3, the photopic b-wave, and
a reduction in the overall index (OP1 ? O-
P2 ? OP3) and a prolongation of mean peak times
of the scotopic OP1, OP2, OP3, OP4 (p\ 0.05). A
questionnaire concerning abnormalities of dopa-
mine-dependent visual functions revealed that PD
patients with abnormal peak times of OP1, OP2, and
OP3 reported non-specific visual disturbances more
frequently in comparison with PD patients with
normal peak times of OPs. Other analyzed pa-
rameters of ERG, DBCVA, RT, and RNFL did not
significantly differ between patients with PD and the
control group.
Conclusion In patients with early PD, bioelectrical
dysfunction of the retina was observed in the ERG test,
probably as a result of dopamine deficiency in the
retina. The results of our study indicate that ERG may
also be a useful tool for understanding the reason for
non-specific visual disturbances occurring in PD
patients.
Keywords Parkinson’s disease  Retinal
bioelectrical function and structure  ERG  OCT
B. Nowacka (&)  W. Lubin´ski
Department of Ophthalmology, Pomeranian Medical




Department of Neurology, Pomeranian Medical
University, Szczecin, Poland
A. Potemkowski
Department of Clinical Psychology, University of
Szczecin, Szczecin, Poland
K. Safranow
Department of Biochemistry and Medical Chemistry,
Pomeranian Medical University, Szczecin, Poland
123
Doc Ophthalmol (2015) 131:95–104
DOI 10.1007/s10633-015-9503-0
Introduction
Parkinson’s disease (PD) is the neurodegenerative
disorder characterized by a deficiency of the neuro-
transmitter—dopamine in the central and peripheral
nervous system, including visual pathways. In the eye,
dopamine is contained in an A18 subtype of amacrine
cells of the retinal inner plexiform layer [1]. Despite of
their low density, their widespread dendritic organi-
zation and long fine axons ensure overlap with
neighboring amacrine cells and bipolar cells and
direct influence through synapses [2]. Moreover, every
type of retinal neuron may be influenced by dopamine
through so-called volume transmission, because it can
diffuse over distance of the entire retinal thickness [1].
As dopamine takes part in light adaptation [1, 3],
spatial contrast sensitivity and color discrimination
[4–6], visuospatial problem solving, spatial working
memory, and oculomotor control [6], many PD
patients, even in the early stages of the disease, may
complain of non-specific visual symptoms. The func-
tional changes may appear even with the normal
morphology of the retina and the optic nerve, probably
as a result of diminished dopaminergic activity in the
visual system. These changes can be detected with the
aid of electrophysiological examinations. A few past
full-field electroretinogram (ERG) studies reported
photopic b-wave amplitude reduction in early PD [7],
as well as in patients with different severities of the
disease [8–10], but there are also study results that
oppose this finding [11–14]. Moreover, Gottlob et al.
[10] and Burguera et al. [8] observed reduced ampli-
tudes not only of the scotopic and photopic b-wave,
but also of the a-wave. On the other hand, Iudice et al.
[15] did not observe any significant differences of
scotopic b-wave amplitude of untreated PD patients
compared with the controlled group. When the
oscillatory potentials (OPs) were studied, Gottlob
et al. [10] observed reduced amplitude of second
oscillatory potential (OP2), while Kupersmith et al.
[16] found no difference between PD and control
subjects. Electrophysiological evidence of visual
pathology in early PD has also been related to delayed
light peak in the electrooculogram (EOG) [7], ampli-
tude reductions in the pattern electroretinogram
(PERG) [17], and delays in visually evoked potentials
(PVEP) [17].
Optical coherence tomography (OCT) is another
method for identifying pathological changes of the
retina of PD patients. OCT has been proposed as a
useful tool for detecting loss of ganglion cells,
secondary to progressive retinal dopaminergic defi-
ciency and amacrine cells’ loss [18]. The paramacular
retinal thickness (RT) and the retinal nerve fiber layer
(RNFL) thickness near the entry of the optic nerve
have been investigated in several studies. However,
their results are inconclusive [19–25], and there are no
data on anatomical changes exclusively in patients
with early PD. Therefore, we decided to determine
whether there are any electrophysiological and
anatomical changes of the retina in patients with early
stages of PD and whether these changes, if present,




Thirty-eight eyes of 20 patients aged 60.6 ± 7.9 years
with early idiopathic PD (1–1.5 according to Hoehn–
Yahr scale, duration of disease under 3 years) and 38
eyes of 20 healthy age- and sex-matched controls
(60.9 ± 7.4 years, p = 0.75) were enrolled in the
study. All participants with any ocular abnormalities
of the retina, optic nerve, and ocular media detected via
indirect ophthalmoscopy, or previous ocular surgery
other than uneventful phacoemulsification, were ex-
cluded from the study. Patients with diagnosed early
idiopathic PD were referred on ophthalmological
examination from the neurological outpatient clinics.
The patients’ duration of PD and general medical
history were recorded. PD staging was assessed with
the modified Hoehn and Yahr (H–Y) scale. Nine of the
PD patients were before anti-parkinsonian therapy and
had not received any drugs yet. The remainder were
under the regimen of anti-parkinsonian treatment.
Seven PD patients received precursor of dopamine (L-
dopa), and in order to prevent the influence of
extraneous dopamine on test results, they were asked
to skip their morning dose of anti-parkinsonian treat-
ment prior to the examination. Four PD patients except
L-dopa were being treated with biperiden or selegilini
hydrochloride, and they were requested to stop the
intake of these medications for at least 24 h. All patients
enrolled in the present study met these requirements.
Patient characteristics are shown in Table 1.
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The study adhered to the tenets of the Declaration
of Helsinki. All subjects participating in this study
gave their informed written consent. The project was
approved by Ethics Committee of the Pomeranian
Medical University.
Procedures
All subjects participating in this study underwent
ophthalmological examination of both eyes, including
assessment of distance best-corrected visual acuity
(DBCVA), slit lamp examination of the anterior and
posterior segment of the eye, evaluation of the
structure of the macula, the paramacular RT and the
peripapillary RNFL thickness in superior, temporal,
inferior, and nasal quadrants (fast algorithms, time-
domain Stratus OCT, Carl Zeiss Meditec), and ERG
(UTAS-E 2000 system, LKC Inc., USA). All pa-
rameters despite stimulus strength (1.6 cd s/m2 in-
stead of 3.0 cd s/m2) were consistent with the current
International Society for Clinical Electrophysiology
of Vision (ISCEV) Standards [26].
Before recording dark-adapted ERG, pupils were
maximally dilated ([6 mm) with 1 % Tropicamidum,
and patients were sitting with eyes closed and covered
with special black goggles for 30 min. After testing in
dark conditions, background light (luminance 32 cd/
m2) of the Ganzfeld bowl was turned on, and 10 min of
light adaptation was performed before recording light-
adapted ERGs. The examination was performed with
the binocular, full-field (Ganzfeld) stimulation. Two
types of electrodes were used: active/reference (right
and left)—bipolar contact lens Burian–Allen elec-
trodes and ground—clip gold cup electrode attached to
the earlobe. Parameters of the recording system were
as follows: amplifiers sensitivity: 10–20–50 lV/div,
filters: 0.3–500 Hz (for OPs extraction: 75–500 Hz),
notch filters: off, time base: 5 ms/div, and artifact
reject threshold: 0 lV. Every response was repeated to
study the reproducibility. One of reproducible wave-
forms was taken for analysis. The flicker response was
averaged at 10 sweeps.
Dark-adapted ERGs
A. Dark-adapted ERG (a dim flash; primarily rod
response)—the stimulus was a dim white flash of
0.012 cd s/m2; analyzed parameters: amplitude
and peak time of the b-wave.
B. Dark-adapted ERG (a strong flash; rod–cone
response)—the stimulus was a white flash of
1.6 cd s/m2; analyzed parameters: amplitude and
peak time of the a- and b-waves.
C. Dark-adapted oscillatory potentials—1.6 cd s/m2
flash stimulation; the second waveform was
retained; analyzed parameters: amplitude and
peak time of the first four oscillatory waves
(OP1, OP2, OP3, OP4) and the overall index (a
sum of OP1 ? OP2 ? OP3 amplitudes) [26].
Light-adapted ERGs
A. Light-adapted ERG (primarily cone response)—
the stimulus was a white flash of 1.6 cd s/m2;
analyzed parameters: the amplitude and peak time
of the a- and b-waves.
B. Light-adapted flicker ERG (cone response)—
flickering 1.6 cd s/m2 flashes presented at a rate
of 30 stimuli per second (30 Hz); during the first
5 s of pre-adaptation waveforms were discarded
Table 1 Characteristics of the study groups and results of the
ophthalmological examinations
PD group Control group p value
Number of eyes 38 38 ns
Age (years) 60.9 ± 7.7 60.6 ± 7.9 ns
Sex (men/women) 12/8 12/8 ns
PD duration (years) 1.7 ± 1.0 – –
Stage of PD (H–Y) 1.1 ± 0.2 – –
DBCVA (log MAR) 0.01 ± 0.02 0.03 ± 0.08 ns
RT (lm) 223.8 ± 14.9 213.8 ± 14.3 ns
RNFL thickness (lm)
Temporal 63.5 ± 14.4 61.5 ± 12.6 ns
Superior 122.4 ± 17.4 115.2 ± 19.6 ns
Nasal 79.2 ± 18.5 72.0 ± 15.0 ns
Inferior 124.5 ± 17.2 119.3 ± 17.3 ns
Quantitative data are presented as mean ± standard deviation.
Qualitative data are presented as number of patients
PD Parkinson’s disease, H–Y Hoeh and Yahr scale, DBCVA
distance best-corrected visual acuity, RT retinal thickness,
RNFL thickness retinal nerve fiber layer thickness, ns not
significant (p[ 0.05)
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in order to reach stable conditions; analyzed
parameters: the peak-to-though amplitude and
peak timing from the midpoint of the stimulus
flash to the following peak, which was calculated
automatically from 10 averaged recordings.
Additionally, PD patients were interviewed as to
the presence of dopamine-dependent visual function
abnormalities: difficulties in light adaptation and
smooth pursuit, decreased contrast sensitivity, and
abnormalities in color vision.
Statistical analysis
Since distributions of most analyzed quantitative
variables were significantly different than normal
distribution (p\ 0.05, Shapiro–Wilk test), the non-
parametric Mann–Whitney U test was used for
comparisons between groups. A p value\ 0.05 was
considered significant. To address the problem of
multiple comparisons, false discovery rate (FDR)
methodology was used [27]. Q values indicating the
expected proportion of incorrectly rejected null hy-
potheses (‘‘false discoveries’’) were calculated for all
comparisons. The q value of an individual hypothesis
test is the minimum FDR at which the test may be
called significant.
In analyzing individual patients’ results, the elec-
trophysiological parameters were considered as nor-
mal if they were between 2.5 and 97.5 percentile.
Results
The distance best-corrected visual acuity was good
in all subjects participating to the study and did not
significantly differ between PD patients and con-
trols. Retinal and RNFL thicknesses’ differences
were also statistically insignificant. The structure of
the macula was normal in all patients. Results of
the above examinations are summarized in Table 1.
Statistically significant ERG differences between
patients with early stages of PD and control subjects
were observed. They contained a reduction in mean
amplitudes of the scotopic a-wave (rod–cone respon-
se), the scotopic oscillatory potentials (OPs)—OP2
and OP3, the photopic b-wave, and reduction in the
overall index (OP1 ? OP2 ? OP3) and a prolonga-
tion of mean peak times of the scotopic OP1, OP2,
OP3, and OP4 (p\ 0.05). It is worth noting that the
scotopic a-wave peak time was at the borderline of
statistical significance (p = 0.07). Other analyzed
parameters of ERG recordings did not significantly
differ between patients with PD and the control group.
After FDR correction for multiple comparisons sig-
nificance (q value\ 0.05) was obtained for three
differences: scotopic a-wave amplitude, scotopic OP1
and OP2 peak times. These differences have the lowest
risk of being false positive. Five additional differences
(scotopic OP3 and OP4 peak times, OP3 amplitude,
the overall index, and photopic b-wave amplitude)
were of borderline significance with q value between
0.05 and 0.1. It means that among the eight differences
with q value\ 0.1, only one of ten (i.e. one differ-
ence) is expected to be found a false positive. The total
number of comparisons was 27. Results of ERG test
are summarized in Table 2. The example of reduced
amplitudes of the scotopic a-wave and the photopic
b-wave, and the abnormal OPs obtained from the eye
of a PD patient in comparison with the normal results
of a control case is shown in Fig. 1.
When each of the 38 examined eyes of 20 PD
patients was analyzed separately, the results from
eight (21 %) eyes of six PD patients deviated from the
normal values for OPs peak times. On this basis, all 20
PD patients were divided into two groups: six patients
with abnormal OPs and 14 patients with normal OPs.
The patients with abnormal OPs more frequently
reported non-specific visual disturbances: difficulties
in light adaptation (3/6 vs. 2/14 patients with abnormal
OPs vs. normal OPs, respectively) and smooth pursuit
(1/6 vs. 0/14 patients), decreased contrast sensitivity
(3/6 vs. 1/14 patients), abnormalities of color vision
(1/6 vs. 0/14 patients). The results of the comparison
of the frequency of dopamine-dependent visual func-
tion abnormalities and the results of ERG—OPs in PD
patients are summarized in Table 3.
Discussion
In this study, it was shown for the first time, that
there were no changes in RT and RNFL thickness in
patients with early stages of PD. The results of
previous OCT studies in patients with more ad-
vanced stages of PD were inconclusive. Some of
these studies using time-domain OCT [19, 20]
pointed at a decreased RNFL thickness in the
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Table 2 Comparison of ERG results from 38 eyes of 20 patients with early stages of PD and controls
Wave Group N M ± SD Min Med Max
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inferior and temporal quadrant. However, some
other studies revealed no difference in the inferior,
superior, nasal, or temporal sectors between PD and
control cases [21, 22]. Inzelberd et al. [19]
suggested that loss of RNFL thickness in PD might
be a result of reduced dopaminergic input to a
subset of ganglion cells, which may cause atrophy,
and localized thinning of RNFL. Also, results of
OCT studies concerning RT measurements in PD
patients are inconclusive. Consistent with our
results, Archibald et al. [22] recently showed no
significant RT changes with time-domain OCT, but
significant differences in macular thickness were
detected with spectral-domain OCT [23, 24]. How-
ever, there is also a study utilizing the same
methodology that opposes this finding [25].
Table 2 continued
Wave Group N M ± SD Min Med Max
























A amplitude, PT peak time, PD Parkinson’s disease, C control, N normal distribution, M ± SD mean ± standard deviation, Min
minimal value, Med median, Max maximum value, Overall index OP1 ? OP2 ? OP3
Statistically significant (bold): * p\ 0.05; ** p\ 0.01; *** p\ 0.001
# Statistically significant (q\ 0.05) after FDR correction for multiple comparisons
^ Borderline statistical significance (q\ 0.1) after FDR correction for multiple comparisons
Fig. 1 Example of reduced
amplitudes of the scotopic
a-wave and the photopic
b-wave, and the abnormal
OPs obtained from the eye
of a PD patient in
comparison with the normal
results of a control case
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The results of our study indicate that even with the
absence of structural changes in the retina, there might
be electrophysiologically detectable dysfunctions in
the retinae of patients with early stages of PD. We
observed a reduction in mean amplitudes of the
scotopic a-wave (rod-cone response), the scotopic
oscillatory potentials (OPs)—OP2 and OP3, the
photopic b-wave, and a reduction in the overall index
(OP1 ? OP2 ? OP3) and a prolongation of mean
peak times of the scotopic OP1, OP2, OP3, and OP4
(p\ 0.05). In the literature, only a few reports can be
found of studies describing ERG recordings in PD
patients in general (advancement of PD ranged from 1
to 4 according to Hoehn–Yahr scale). Moreover,
patients were examined in the course of their treatment
with anti-parkinsonian drugs (including L-dopa),
which might have influenced ERG results. It is known
from a study by Jaffe et al. [28] that exogenous
dopamine enhanced the photopic b-wave almost by
one-fourth. Moreover, in some studies, the experimen-
tal group consisted of patients with parkinsonism of
other than idiopathic etiologies (for example arte-
riosclerotic) [12–14]. In the course of PD, the reduced
amplitudes of the scotopic and photopic a- and
b-waves were observed [8–10]. However, there are
also studies which did not confirm these findings [11–
14]. When OPs were analyzed, no difference in OPs
peak times were found [10, 16]. However, the reduced
amplitude of the photopic OP2 was observed [10].
According to our best knowledge, there is only one
past study concerning ERG changes in untreated
patients with stage I of PD according to the Hoehn–
Yahr scale. Despite some differences in the method-
ology (e.g., stimulation of red flash), Ikeda et al. [7]
observed significant changes in b-wave amplitude in
early PD patients compared with controls, which is
consistent with our results. Our findings are also
consistent with results of Iudice et al [15] who did not
observe any significant differences in the scotopic
b-wave amplitude of untreated PD patients compared
with controls, but the degree of advancement of PD
was not specified.
In this study, we observed reduced amplitude of
scotopic a-wave (rod-cone response) in PD group.
Moreover, when we carefully analyzed collected data of
scotopic a-wave, we observed that 79 % of eyes of the
controls achieved the amplitude of more 165 lV,
whereas only 29 % eyes of PD patients showed these
results. The difference was statistically significant
(Mann–Whitney U test, p = 0.00018). The results of
animal studies indicate that a-wave (more precisely the
fast P-III component of the ERG) mostly reflects light-
induced activity of the photoreceptors [29]. Meanwhile,
photoreceptors seems to be a subject of a number of
dopamine-mediated mechanisms. Dopamine, acting
through a D2 receptor, modulate the voltage-gated
calcium current [30], a hyperpolarization-dependent
current [31], and coupling between rods and cones [32].
Moreover, Shulman and Fox [33] report that activation
of the D4 receptor inhibits the Na/K ATPase of rat rods.
In relation to considerations of dopamine receptors,
their number and/or sensitivity may be up-regulated
when dopamine concentrations are very low [34]. The
retinal dopamine seems to be a primary factor coordi-
nating shift from nighttime to daytime vision, thus
functional transition from a rod- to cone-dominated state
[35, 36]. Therefore, it seems sensible to hypothesize that
lower concentration of retinal dopamine in course of PD
may cause disruption of one or more dopamine-
mediated mechanisms in the photoreceptors, what was
Table 3 Comparison of the frequency of dopamine-dependent visual function abnormalities and the results of ERG—oscillatory
potentials in 20 PD patients
Visual symptoms ERG—OPs
: PT (n = 6/20) normal PT (n = 14/20)
Difficulties in light adaptation 3/6 (50 %) 2/14 (14.3 %)
Decreased contrast sensitivity 3/6 (50 %) 1/14 (7.1 %)
Abnormalities of color vision 1/6 (16.7 %) 0/14 (0 %)
Difficulties in smooth pursuit 1/6 (16.7 %) 0/14 (0 %)
Data are presented as number of patients and percentage
PD Parkinson’s disease, PT peak time, OPs oscillatory potentials, n number of patients
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observed as reduction in the scotopic a-wave amplitude
in the present study. We also showed increased peak
times and reduced amplitudes of the OPs. On the basis of
results of previous studies, OPs are thought to reflect
neural interactions between amacrine, ganglion, and
bipolar cells, and the ON pathways appear to play a
critical role in OPs generation [37–40]. Meanwhile,
dopaminergic amacrine cells A18 are definitely in-
volved in ON pathways [41]. Results of animal studies
demonstrated that despite the anatomical projections of
A18 cells in the off sublamina of the inner retina, no OFF
responses were recorded in dopaminergic amacrine
cells [41]. Moreover, results of animal studies using
reserpine—an indole alkaloid causing depletion of
monoamine neurotransmitters (dopamine, nore-
pinephrine, serotonin) in the synapses—showed ab-
sence of OPs [42, 43]. Oscillatory potentials reappeared
when L-dopa was injected intravitreally. Thus, it is
reasonable to suppose that dopaminergic amacrine cells
A18 make a contribution to OPs generation. We also
observed reduction in photopic b-wave. The results of
animal studies indicate that cellular origin of b-wave are
mostly the ON bipolar cells [44–46]. The results of other
animal studies on the contribution to the shape of the
ERG b-wave by third-order retinal neurons indicate that
amacrine cells might modulate its kinetics and ampli-
tude [47]. Moreover, as dopamine takes part in light
adaptation [1, 3], it may be assumed that impairment of
this process due to decreased dopamine concentration in
the PD retinas might cause photopic b-wave amplitude
reduction. In a present study, PD patients also achieved
worse results of amplitude and peak time of flicker ERG
than controls, but the difference was not statistically
significant. We assume that if the examined sample was
larger, the difference could achieve statistical sig-
nificance. Although the complexity of dopamine func-
tion at multiple levels in the outer and inner retina in
producing alterations to the flow of visual information, it
can be supposed that decreased dopamine concentration
in PD may be a cause of presented changes in ERG.
The analysis of individual PD patients’ ERG results
revealed that patients with abnormal OPs more
frequently reported dopamine-dependent visual dis-
turbances, such as difficulties in light adaptation and
decreased contrast sensitivity in comparison with
individuals in the subgroup with normal OPs peak
times. The results of the previous studies indicate that
visual dysfunction in the course of PD appeared to be
due to retinal dopaminergic deficiency and impair-
ment of central visual system [48]. Our results suggest
that in the eyes of PD patients with dopamine-
dependent visual function abnormalities, this
dopaminergic retinal defect is present. Especially,
that electrical activity of the A18 cells is associated
with dopamine release from dopaminergic neurons in
the brain [49, 50]. Further research is needed to
determine if higher doses of exogenous dopamine
reduces the occurrence of these visual disturbances.
Conclusion
The result of this study confirms previous findings [7–
10] that there is a dopaminergic defect of the PD
patients’ retina, and it could be detected by ERG.
However, we expanded our knowledge in that even in
patients with early PD, there is bioelectrical dysfunc-
tion of the retina, and it is not only manifested by
b-wave reduction as Ikeda et al. [7] observed, but also
by reduction in scotopic a-wave and OPs amplitudes
and prolongation of scotopic OPs peak times. The
ERG may be also considered as a useful tool for
understanding the reason of non-specific visual dis-
turbances occurring in PD patients. However, further
research is needed to confirm our findings.
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